Exploiting SARS-CoV-2 Replication Cycle for COVID-19 Therapies

Ismail I. Al-Janabi
{"title":"Exploiting SARS-CoV-2 Replication Cycle for COVID-19 Therapies","authors":"Ismail I. Al-Janabi","doi":"10.54133/ajms.v1i.52","DOIUrl":null,"url":null,"abstract":"The tail end of 2019 saw the identification of SARS-CoV-2 as the causative virus of COVID-19, which was followed in March 2020 by the assignment of pandemic status to this disease. COVID-19 has exacted terrible tolls on the lives, health, and economies of nearly every country on the planet since then. The major focus in fighting the pandemic has been on the fast development and deployment of vaccines. Despite the undoubted success of vaccines, a few COVID-19 cases will continue to be encountered that require medical interventions. The field of pharmacological treatment has been largely set aside with no emerging specific and effective therapies that are tailored and designed to combat SARS-CoV-2. This narrative review looks at pharmacological therapies that target parts of the viral replication cycle or counteract the body’s response to the presence of the virus. A literature search was undertaken using PubMed and Google Scholar databases to identify relevant medicinal therapies and clinical studies for the management of COVID-19.","PeriodicalId":433524,"journal":{"name":"Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 )","volume":"20 2","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 )","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54133/ajms.v1i.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The tail end of 2019 saw the identification of SARS-CoV-2 as the causative virus of COVID-19, which was followed in March 2020 by the assignment of pandemic status to this disease. COVID-19 has exacted terrible tolls on the lives, health, and economies of nearly every country on the planet since then. The major focus in fighting the pandemic has been on the fast development and deployment of vaccines. Despite the undoubted success of vaccines, a few COVID-19 cases will continue to be encountered that require medical interventions. The field of pharmacological treatment has been largely set aside with no emerging specific and effective therapies that are tailored and designed to combat SARS-CoV-2. This narrative review looks at pharmacological therapies that target parts of the viral replication cycle or counteract the body’s response to the presence of the virus. A literature search was undertaken using PubMed and Google Scholar databases to identify relevant medicinal therapies and clinical studies for the management of COVID-19.
利用SARS-CoV-2复制周期治疗COVID-19
2019年底,SARS-CoV-2被确定为COVID-19的致病病毒,随后在2020年3月,该疾病被确定为大流行病毒。自那时以来,COVID-19给地球上几乎每个国家的生命、健康和经济造成了可怕的损失。抗击大流行的主要重点是快速开发和部署疫苗。尽管疫苗取得了毋庸置疑的成功,但仍会遇到一些需要医疗干预的COVID-19病例。药物治疗领域在很大程度上被搁置了,没有针对SARS-CoV-2量身定制和设计的新出现的特定和有效的疗法。这篇叙述性综述着眼于针对病毒复制周期的部分或抵消人体对病毒存在的反应的药物治疗。利用PubMed和Google Scholar数据库进行文献检索,确定COVID-19管理的相关药物治疗和临床研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信